TRAVERE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $154.9M | $133.6M | $99.9M | $28.2M | $0 | $0 | $0 |
| Cost of Revenue | $3.6M | $4.6M | $2.2M | $571.0K | $0 | — | — |
| Gross Profit | $151.3M | $129.0M | $97.7M | $27.6M | $0 | — | — |
| Gross Margin | 97.7% | 96.6% | 97.8% | 98.0% | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $78.2M | $70.8M | $50.4M | $47.8M | $7.1M | $662.5K | — |
| SG&A Expense | $101.3M | $91.9M | $79.5M | $59.6M | $17.7M | $29.6M | $12.7K |
| Operating Income | $-53.8M | $-58.2M | $-50.7M | $-79.8M | $-24.8M | $-30.3M | $-23.0K |
| Operating Margin | -34.7% | -43.6% | -50.8% | -283.0% | — | — | — |
| Interest Expense | $4.4M | $4.7M | $7.7M | $7.4M | $0 | $84.1K | — |
| Pretax Income | $-58.4M | $-57.6M | $105.5M | $-113.4M | $-34.5M | $-30.3M | — |
| Income Tax Expense | $1.4M | $-9.7M | $-11.8M | $-2.5M | $76.0K | — | — |
| Net Income | $-59.7M | $-47.9M | $117.2M | $-110.9M | $-34.6M | $-30.3M | $-23.0K |
| Net Margin | -38.6% | -35.9% | 117.4% | -393.4% | — | — | — |
| EPS (Basic) | $-1.54 | $-1.29 | $3.49 | $-4.43 | $-2.44 | $-8.29 | — |
| EPS (Diluted) | $-1.54 | $-1.29 | $3.17 | $-4.43 | $-2.44 | $-8.29 | — |
| Shares Outstanding (Basic) | 38.8M | 37.0M | 33.6M | 25.1M | 14.2M | 9.0M | 4.0M |
| Shares Outstanding (Diluted) | 38.8M | 38.3M | 37.6M | 25.1M | 14.2M | 9.0M | 4.0M |
| Dividends Per Share | — | — | — | — | — | — | — |